
Reviewing Key Trials Shaping IO Monotherapy in Advanced Lung Cancer
First-line treatment for advanced non-small cell lung cancer (NSCLC) has evolved significantly with immunotherapy (IO) becoming a cornerstone for patients with high PD-L1 expression. During a Community Case Forum event, moderator Bruna Pellini, MD, …